Inhibition of vascular endothelial growth factor alleviates neovascular retinopathy with regulated neurotrophic/proinflammatory cytokines through the modulation of DBI‐TSPO signaling

Abstract Diazepam binding inhibitor (DBI)‐translocator protein (18kDa) (TSPO) signaling in the retina was reported to possess coordinated macroglia‐microglia interactions. We investigated DBI‐TSPO signaling and its correlation with vascular endothelial growth factor (VEGF), neurotrophic or inflammatory cytokines in neovascular retinopathy, and under hypoxic conditions. The vitreous expression of DBI, VEGF, nerve growth factor (NGF), and interleukin‐1beta (IL‐1β) were examined in proliferative diabetic retinopathy (PDR) patients with or without anti‐VEGF therapy and nondiabetic controls. Retinal DBI‐TSPO signaling and the effect of the anti‐VEGF agent were evaluated in a mouse model of oxygen‐induced retinopathy (OIR). Interactions between Müller cell‐derived VEGF and DBI, as well as cocultured microglial cells under hypoxic conditions, were studied, using Western blot, real‐time RT‐PCR, enzyme‐linked immunosorbent assay (ELISA), flow cytometry, and immunofluorescent labeling. Results showed that vitreous levels of DBI, VEGF, NGF, and IL‐1β were significantly higher in PDR patients compared with controls, which further changed after anti‐VEGF therapy. A statistical association was found between vitreous DBI and VEGF, NGF, IL‐1β, and age. The application of the anti‐VEGF agent in the OIR model induced retinal expression of DBI and NGF, and attenuated inflammation and microglial cell activation. Inhibition of Müller cell‐derived VEGF could increase its DBI expression under hypoxic conditions, while the DBI‐TSPO signaling pathway is essential for anti‐VEGF agents exerting anti‐inflammatory and neuroprotective effects, as well as limiting inflammatory magnitude, promoting its neurotrophin production and anti‐inflammatory (M2) polarization in microglial cells. These findings suggest the beneficial effect of anti‐VEGF therapy on inflammation and neurotrophy of retinal glial cells through modulation of the DBI‐TSPO signaling pathway.